用ACT-1014-6470建模时间延迟度-QT效应,这是一种新的口服补充因子5a受体1 (C5a1受体) 抗剂
Marion Anliker-Ort1,2, Chih-Hsuan Hsin1, Andreas Krause1
1Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Pharmacology research & perspectives
|July 20, 2023
概括
补充因子5a受体1抗剂ACT-1014-6470表现出良好的耐受性. 虽然通常是安全的,但长时间的剂量显示了纠正的QT间隔 (QTcF) 的延迟,剂量依赖的增加,这需要在未来的试验中仔细选择剂量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
- 心血管安全心血管安全
背景情况:
- ACT-1014-6470是一种新的口服抗剂,向补充因子5a受体1.
- 了解其心动力学影响,特别是QT间隔的影响,对于安全的临床开发至关重要.
研究的目的:
- 在健康人群中评估ACT-1014-6470的心动力学安全性.
- 评估单次和多次上升剂量对心电图 (ECG) 参数的影响,特别是QT间隔.
主要方法:
- 进行了单剂量和多剂量上升剂量研究.
- 使用分类,形态和按时点方法分析了24小时的霍尔特心电图记录.
- 进行度-QT建模和模拟,以预测不同剂量和治疗方案的影响.
主要成果:
- 在所有测试剂量中,ACT-1014-6470的耐受性很好.
- 在分类和形态分析中,没有发现对心电图参数的显著影响.
- 单剂后观察到与安慰剂纠正的QTcF的延迟,剂量依赖的增加,并且持续每天两次剂量,表明非度依赖的效应.
结论:
- 度-QT建模预测,较低的剂量 (例如,每天一次30毫克,10毫克每天两次) 不会超过监管的QTcF值.
- 这些剂量可以达到足够的目标参与,同时可能减轻QT责任.
- 这些发现为未来临床试验的剂量选择提供了信息,以平衡疗效和安全.
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
606
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
606
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.3K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.3K
Quantitative Aspects of Drug-Receptor Interaction
1.0K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.0K
The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.0K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.0K


